Episode Details
Back to Episodes
AGORACOM Talks | Small Cap Weekly Roundup: Standout Companies of the Week Ending May 16, 2025!
Description
AGORACOM TALKS Weekly Roundup Catch up on the biggest developments from small-cap leaders making major moves across materials, cleantech, biotech, and exploration:
HPQ Silicon (TSXV: HPQ | OTCQX: HPQFF)
HPQ and PyroGenesis Hit Major Milestone in Fumed Silica Production HPQ and PyroGenesis have successfully produced and recovered fumed silica using a proprietary low-emission process, demonstrating scalability. This innovation has the potential to reshape the multi-billion-dollar fumed silica market by significantly reducing both production costs and carbon emissions. Testing is ongoing, with samples expected to be sent to third parties for evaluation.
Renforth Resources (CSE: RFR | OTCQB: RFHRF)
Renforth Confirms Critical Mineral Potential with Bark Sampling Renforth’s unique tree bark sampling across its Victoria structure in Quebec revealed promising signs of nickel, cobalt, platinum, and more—without the need for drilling. The technique is low-cost, low-impact, and helping fast-track exploration across the Malartic Metals Package.
Zefiro Methane (CBOE Canada: ZEFI | OTCQB: ZEFIF)
Zefiro Reports $6.9M USD Revenue and Expands U.S. Operations Zefiro continues its mission to plug abandoned oil wells and monetize methane emissions. Now active in six U.S. states, the company is preparing carbon credit delivery, deploying AI-driven tools, and solidifying its role in the clean-tech carbon market.
PyroGenesis (TSX: PYR | OTCQX: PYRGF)
$52M Backlog and Clean Tech Momentum at PyroGenesis PyroGenesis Inc. reported its Q1 2025 financial results, highlighting a revenue of $3 million—a 14% decrease compared to the same quarter in 2024. Despite the revenue decline, the company improved its gross margin to 27%, up from 21.7% in Q1 2024.
Quantum Biopharma (CSE: QNTM | NASDAQ: QNTM)
Quantum Advances MS Drug with Preclinical Milestone Quantum completed key 90-day toxicology studies for Lucid-MS, a first-in-class Multiple Sclerosis treatment. With an FDA submission expected this year, the company is preparing for Phase 2 human trials—a critical step that could attract strategic partners in the biotech space.